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Abstract: Hot-melt extrusion (HME) is the most preferred and effective method for manufacturing
amorphous solid dispersions at production scale, but it consumes large amounts of samples when
used for formulation development. Herein, we show a novel approach to screen the polymers by
overcoming the disadvantage of conventional HME screening by using a minimum quantity of
active pharmaceutical ingredient (API). Vacuum Compression Molding (VCM) is a fusion-based
method to form solid specimens starting from powders. This study aimed to investigate the
processability of VCM for the creation of amorphous formulations and to compare its results with
HME-processed formulations. Mixtures of indomethacin (IND) with drug carriers (Parteck® MXP,
Soluplus®, Kollidon® VA 64, Eudragit® EPO) were processed using VCM and extrusion technology.
Thermal characterization was performed using differential scanning calorimetry, and the solid-state
was analyzed via X-ray powder diffraction. Dissolution studies in the simulated gastric fluid were
performed to evaluate the drug release. Both technologies showed similar results proving the
effectiveness of VCM as a screening tool for HME-based formulations.
Keywords: polyvinyl alcohol; screening tool; hot-melt extrusion; amorphous solid dispersion;
formulation development
1. Introduction
In 1971, hot-melt extrusion (HME) was introduced as a formulation technology platform for the
pharmaceutical industry [1]. Neither solvents nor complicated processing steps are required in HME
to formulate a specialized drug delivery formulation. It can be used for the formulation of various
drug delivery systems, but one of its significant uses is to improve the solubility of poorly soluble
drugs [2]. This is one of the key challenges in today’s research in formulation and development. Most
of the new drugs under development have poor solubility of the active pharmaceutical ingredients [3].
The solubility and permeability of a drug are categorized by the biopharmaceutical classification system
(BCS) into four classes based on its aqueous solubility and intestinal permeability [4]. The percentage
of new molecular entities with poor solubility is likely to increase due to development in combinatorial
chemistry and the significant importance of lipophilic receptors [5]. The creation of amorphous
solid dispersions (ASD) is one way of formulating such poorly soluble drugs [6]. The solubility and
bioavailability can be improved by orders of magnitudes via HME [7]. The solid-state of the poorly
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soluble crystals is changed via HME. They are dissolved within the polymer matrix when processed in
the molten state. Once cooled down, the individual molecules are entrapped within the polymer matrix,
forming a dispersed solid solution. When the solid solution is dissolved, the polymer matrix controls
the dissolution rate and releases the individual molecules of the active substance. High supersaturation
levels can be maintained over a long time when suitable excipients are selected. Novel generations
of amorphous solid dispersions are aiming to improve the dissolution profile of the carrier matrix
by applying ingredients that provide additional surface activity or self-emulsifying properties [8].
Despite this advantage, it can also increase the risk of recrystallization during storage. Amphiphilic
polymers can provide a relevant advantage, as no additional excipients are required to ensure the
supersaturation of low soluble compounds.
Even with increasing demand, HME lacks reliable tools for formulation development, which
allows access to reliable material data on a small scale. The HME technology was developed for
processing plastics, and most of the development efforts were put on efficiency and maximizing the
throughput [9]. When it was brought into the pharmaceutical labs, the smallest plastic extruders
were adapted to suit the pharmaceutical manufacturing practices. To address the need to perform
small-scale screening, the equipment was downsized in dimensions or its concept slightly changed
to reduce the minimum amount of material required to generate initial results [10]. Small-scale
extruders require at least a few grams of a material to allow first fusion-based investigations. The large
fraction of the material, however, is lost during the startup phase or remains in the dead zone of
the extruder. Formulation development with new chemical entities (NCEs) with this limitation is
impractical as the available quantity of the Active Pharmaceutical Ingredient (API) is the limiting
factor. Thus, to develop HME-based formulations comprising NCE, material sparing selection tools are
necessary [11]. The HME technology is already quite established with several products like Lacrisert®,
Kaletra®, Nucynta®, NuvaRing®, and Zythromax® in the market [12].
1.1. Hot-Melt Extrusion
Very few articles are published with the use of HME in first stage investigations. Some reports use
a combined approach of hot stage microscopy and 5 mm twin-screw extruders in their study to observe
the change in crystal form and dissolution of the sample under the influence of the temperature for the
development of scale-up [11,13]. The development of implants by hot-melt extrusion necessitated the
use of small-scale extruders with small batch sizes. For the predictive formulation of protein-loaded
implants, a 9-mm twin-screw extruder was used [14]. To determine operational and performance
qualification on mixing in solid dispersion preparation in early-stage HME development, a conical
twin-screw extruder was utilized [15].
1.2. Differential Scanning Calorimetry
Differential scanning calorimetry (DSC), an established analytical method, is one of the many
thermal methods used as a screening tool to predict the drug-polymer solubility [16]. Experimental DSC
data was used to predict a drug-polymer phase diagram and miscibility for Felodipine and polyacrylic
acid [17]. Knopp et al. predicted drug-polymer solubility at elevated temperatures from DSC data
for binary systems of five model drugs with PVP and PVA [18]. Similarly, for HME formulations,
the solubility of crystalline drugs in the polymer was determined by a combined approach of DSC
measurements and a reliable mathematical algorithm to determine a complete solubility of a drug in a
polymer [19]. The solubility measurements for the compounds with very low absolute solubilities or
exhibiting small changes in solubilities with temperature cannot give reliable results when analyzed
by DSC [20].
1.3. Solvent Casting
Solvent casting is usually applied to generate the first insights into a new API/carrier formulation.
However, for a fusion-based product via HME, its results might deviate. A recent publication combines
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solvent casting with a simplified extrusion step to become a fusion-based screening method [21]. Novel
approaches are also combining rapid solvent evaporation methods with an additional heating step,
which is quite successful in estimating formulation performance [22]. To utilize a minimum amount of
drug, some research reports a high throughput screening technology developed by utilizing a 96 well
plate system to identify optimal drug load and polymer using a solvent casting method [23].
One drawback of solvent casting is to find a common solvent where the polymers and drug
substances together will be solubilized. Especially for hydrophilic polymers, this proves to be
a challenge.
1.4. Vacuum Compression Molding
To overcome the above limitation of established screening tools, a novel approach to screen the
new chemical entity with the polymer can be done using Vacuum Compression Molding (VCM).
VCM is a fusion-based method to form solid specimens starting from powders (Figure 1). The process
was first introduced in 2014 for sample preparation for rheological measurements of pharmaceutical
polymers [24]. For the rheological measurement discs with 25 mm were introduced.
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results. They require diffusion as the dominant mixing mechanism to obtain extrusion-like results.
Hence, preconditioning of the powder before VCM processing is required when formulations with
several components are molded to obtain homogeneous samples. The preconditioning can be obtained
via cryogenic milling as it can alter the polymorphic structures [25].
The processing towards a solid form devoid of air inclusions was not possible in a lossless manner
before the introduction of VCM. The VCM process has attracted the attention of several research groups
and has been successfully applied to the screening of HME formulations like multilayer intravaginal
rings [26]. Another group was speeding up the development of abuse-resistant formulations [27].
Evans et al. used VCM for material characterization to determine the solid density of API-loaded
formulations, which was subsequently fed into a 1D simulation software of extruders to predict
processing behavior best possible [28]. Since VCM results in samples with a defined surface area
which corresponds to the cylinder surface, it enables intrinsic dissolution testing. It allows eliminating
surface effects on the dissolution tests. The dissolution of polymer formulations is a complex topic
and is described in several articles [29–31]. Insights can be obtained by dissolution measurements on
samples with defined geometries. Dissolution mechanisms like surface erosion, bulk erosion, swelling,
or diffusion behavior can be studied on quickly accessible VCM samples. Dissolution tests on the VCM
samples enable direct performance comparison. Results can be used to tailor the particle size of a final
dosage form. If powder or granules are required for the development when a conventional compacted
tablet is desired, VCM samples of example 2–5 g per batch can be milled afterwards and used for the
development tasks.
The objective of the study was to investigate the VCM processability for ASD and to compare
its results with HME-processed formulations. Mixtures of indomethacin (IND) with drug carriers
(Parteck® MXP, Soluplus®, Kollidon® VA 64, Eudragit® EPO) were processed using VCM and
extrusion technology. From the literature, it was found that indomethacin can form a stable ASD
with Soluplus®, Kollidon® VA 64, and Eudragit® EPO. These excipients were able to enhance the
solubility and inhibit crystallization for indomethacin. Until now, the interaction of Parteck® MXP
and indomethacin has not yet been investigated. This paper gives insight into ASD using Parteck®
MXP. The thermal characterization of the ASD was performed using differential scanning calorimetry
and X-ray powder diffraction. The drug release performances were evaluated in simulated gastric
fluid [32–34].
2. Materials and Methods
2.1. Materials
Indomethacin was obtained from Sigma-Aldrich (St. Louis, MO, USA). Parteck® MXP was
purchased from EMD Millipore Sigma (Darmstadt, Germany). Soluplus® and Kollidon® VA-64
were purchased from BASF (Ludwigshafen, Germany). Eudragit® EPO was purchased from Evonik
Industries (Essen, Germany). The marketed products (Indo-CT 50 mg capsules) were purchased
from AbZ Pharma (Ulm, Germany). All other reagents were of either high-performance liquid
chromatography (HPLC) or analytical grade.
2.1.1. Active Pharmaceutical Ingredient (API)
The model API used in this study was indomethacin (IND) which is a BCS class II compound.
Its physicochemical properties are summarized in Table 1. Indomethacin is a potent non-steroidal
anti-inflammatory drug [35]. It is poorly water-soluble with low glass transition temperature and
thermally stable, making it a good choice as a model drug for amorphous solid dispersions [36].
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Table 1. Physicochemical properties of model drug.
API Mw (g/mol) logP Tm (◦C) Tg (◦C) pKa SGF Solubility [37]
Indomethacin 357.8 4.27 155 ± 0.1 49 ± 0.1 4.5 0.004 g/1000 g
2.1.2. Carriers
The excipients selected for the present study were Kollidon® VA 64
a copovidone-(vinylpyrrolidone-vinyl-acetate), Soluplus® a graft copolymer
(polyvinyl-caprolactam-polyvinyl-acetate-polyethylene-glycol), Parteck® MXP (polyvinyl-alcohol),
and Eudragit® EPO (poly-methyl-methacrylate). The physicochemical properties of the excipients are
mentioned in the Table 2.













Parteck®MXP [38] Non-ionic 32,000 54 250 Soluble
Soluplus® [39] Non-ionic 118,000 65–70 250 Soluble
Kollidon®VA-64 [39] Non-ionic 45,000 100 230 Soluble
Eudragit® EPO [40] Ionic 47,000 48 200 Insoluble
2.1.3. Marketed Drug Product for Reference
Indo-CT 50 mg capsules were used as a reference in the release study. They are 50 mg hard
capsules with indomethacin as the active ingredient. It is used for symptomatic treatment of pain
and inflammation.
2.2. Processing Methods
2.2.1. Preparation of Cryo-Milled Mixtures for VCM Preparation-Preconditioning of the Samples
Polymer–Indomethacin (30% w/w) binary mixtures were weighed and then mixed in a Turbula®
Mixer (Willy A. Bachofen AG, Muttenz, Switzerland) for 5 min. The mixture was then cryo-milled
with liquid nitrogen in Ultra-Centrifugal Mill ZM-200 (Retsch GmbH, Haan, Germany) at 18,000 rpm
and sieved through a mesh size of 250 µm.
2.2.2. Vacuum Compression Molding (VCM)
The MeltPrep® VCM Tool consisted of a sample holder, piston, and lid. The sticking of the sample
during the preparation was prevented using separation foils. The sample holder was connected to a
vacuum source. The cryo-milled mixture was filled into the sample holder which provided amorphous
samples of 8 mm and 20 mm in diameter. The 8mm discs were intended to provide intrinsic-like
dissolution, and the 20 mm discs were further processed via milling to create enough material to allow
a direct comparison between milled extrudate and milled VCM material. The piston provided the
pressure on the sample, which was heated on the hot plate until a homogenous mixture was obtained.
The heating process was followed by rapid cooling to get the final product. Table 3 summarizes the
parameters from MeltPrep® samples with 20 mm and 8 mm in diameter. Target temperatures and
respective heating times were adapted and optimized for the individual polymers.
Samples produced via VCM have a defined geometry and yield transparent glasslike discs once
amorphous systems are obtained. The circular cross-section for 25 mm discs, as it was initially
introduced, is 490 mm2 so that for materials with densities of around 1 g/cm3, 1 g is enough to obtain
a solid disc with a height of around 2 mm. The VCM process has attracted the attention of several
pharmaceutical research groups quickly as it offers extrusion-like results and the required material
amount is comparatively lower to the existing extrusion methods.
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Table 3. Processing parameter of VCM samples.
Polymers









Parteck® MXP 230 5 230 5
Soluplus® 170 5 170 4
Kollidon® VA-64 160 5 160 4
Eudragit® EPO 190 5 190 4
The amounts can be drastically reduced further by simply reducing the disc dimensions to smaller
diameters, as it will be shown during the study. This small disc’s diameter (e.g., 2 or 5 mm) enables
sample preparation of small quantities starting at ranges of 10 mg and, in addition„ an opportunity to
meet similar material demands compared to solvent casting methods.
2.2.3. Hot-Melt Extrusion (HME)
For the extrusion process, the pre-blended physical drug-polymer mixture was fed into the
hopper. Each of these resultant drug-polymer binary mixtures containing 30% w/w of the drug was
extruded utilizing an 11 mm co-rotating Pharma twin-screw extruder and Congrav twin-screw feeder
(Thermo Fisher Scientific®, Waltham, MA, USA) equipped with a 2-mm round opening die. Differential
scanning calorimetry was utilized to determine the extrusion processing temperature range. The target
temperature for extrusion was above the melting point of indomethacin. For Soluplus®, Kollidon®
VA 64 and Eudragit® EPO were at about 160 ◦C, anticipating the additional heat impact due to shear
forces. For Parteck® MXP, the temperature profile needed to be increased to overcome the polymer’s
semi-crystalline alignment. Hence, the extrusion temperature was set at 190 ◦C. A standard screw
configuration consisting of conveying and kneading elements was used (Figure 2) at a screw speed of
200 RPM. A constant feed rate of 0.2 kg/h was employed for all formulations. The process parameters
were recorded, and the conditions of the steady-state operation are given in Table 4.
Pharmaceutics 2020, 12, x 6 of 17 
 
Samples produced via VCM have a defined geometry and yield transparent glasslike discs once 
amorphous systems are obtained. The circular cross-section for 25 mm discs, as it was initially 
introduced, is 490 mm2 so that for materials with densities of around 1 g/cm3, 1 g is enough to obtain 
a solid disc with a height of around 2 mm. The VCM process has attracted the attention of several 
pharmaceutical research groups quickly as it offers extrusion-like results and the required material 
amount is comparatively lower to the existing extrusion methods. 
The amounts can be drastically reduced further by simply reducing the disc dimensions to 
smaller diameters, as it will be shown during the study. This small disc’s diameter (e.g., 2 or 5 mm) 
enables sample preparation of small quantities starting at ranges of 10 mg and, in addition,, an 
opportunity to meet similar material demands compared to solvent casting methods.  
2.2.3. Hot-Melt Extrusion (HME) 
F r the extrusion process, the pre-blended physical drug-polymer mixture was fed into the 
hopper. Each of these resultant drug-polymer binary mixtures containing 30% w/w of the drug was 
extruded utilizing an 11 mm co-rotating Pharma twin-screw extruder and Congrav twin-screw feeder 
(Thermo Fisher Scientific®, Waltham, MA, USA) equipped with a 2-mm round opening die. 
Differential scanning calorimetry was utilized to determine the extrusion processing temperature 
range. The target temperature for extrusion was above the melting point of indomethacin. For 
Soluplus®, Kollidon® VA 64 and Eudragit® EPO were at about 160 °C, anticipating the additional heat 
impact due to shear forces. For Parteck® MXP, the temperature profile needed to be increased to 
overcome the polymer’s semi-crystalline alignment. Hence, the extrusion temperature was set at 190 
°C. A standard screw configuration consisting of conveying and kneading elements was used (Figure 
2) at a screw speed of 200 RPM. A constant feed rate of 0.2 kg/h was employed for all formulations. 
The process parameters were recorded, and the conditions of the steady-state operation are given in 
Table 4. 









All The Zones (°C) 




Parteck® MXP 8–10 181 190 20 1–2 
Soluplus® 1 151 160 24 1–4 
Kollidon® VA 64 0–1 152 160 40 2–4 
Eudragit® EPO 0 152 160 43 2–6 
 
Figure 2. Screw configuration for Thermo Fisher Scientific® Pharma 11-mm extrusion. 
2.3. Characterization Methods 
2.3.1. Physical Characterization of the VCM Samples 
The VCM samples were characterized for the uniformity of weight using a Mettler Toledo® 
analytical balance. The before and after sample weights were statistically assessed via a two-tailed 
paired t-test (IBM® SPSS® Statistics 25, Chicago, IL, USA, 2017). The significance threshold was set at 
a p-value of 0.05. The samples were visually inspected for transparency, potential recrystallization, 
and bubbles. 
  
Figure 2. Screw configuration for Thermo Fisher Scientific® Pharma 11-mm extrusion.







All The Zones (◦C)
Torque % of
Max. Torque (Nm)
Parteck® MXP 8–10 181 190 20 1–2
Soluplus® 1 151 160 24 1–4
Kollidon® VA 64 0–1 152 160 40 2–4
Eudragit® EPO 0 152 160 43 2–6
2.3. Characterization Methods
2.3.1. Physical Characterization of the VCM Samples
The VCM samples were characterized for the uniformity of weight using a Mettler Toledo®
analytical balance. The before and after sample weights were statistically assessed via a two-tailed
paired t-test (IBM® SPSS® Statistics 25, Chicago, IL, USA, 2017). The significance threshold was set at
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a p-value of 0.05. The samples were visually inspected for transparency, potential recrystallization,
and bubbles.
2.3.2. Differential Scanning Calorimetry (DSC)
The thermal properties of the polymer excipients, API, and samples prepared in the present
study were investigated using a DSC 3+ differential scanning calorimeter (Mettler-Toledo®, Giessen,
Germany). Nitrogen was used as the purge gas at a flow rate of 50 mL/min. For sample analysis, 5–7 mg
samples were accurately weighed and sealed inside aluminum pans. The lids were pierced by the
autosampler before the measurement was initiated. For thermal characterization, pure indomethacin
and the milled VCM and HME materials were heated at 10 ◦C/min from 25 to 300 ◦C. Results were
analyzed using the STARe SW 16.00 software (Mettler-Toledo®, Giessen, Germany).
2.3.3. PXRD Analysis
PXRD patterns were recorded on a Stoe StadiP® 611 instruments (Stoe, Germany) equipped with
a Cu radiation source (λ = 1.54 Å) and a Mythen1K Si-strip detector. Measurements were conducted in
transmission and at an acceleration voltage of 40 kV and a current of 40 mA. Scanning was performed
over an angle range of 2θ at a step size of 0.015◦ and dwell time of 0.5 s. The results were analyzed
using the Powdat software.
2.3.4. Dissolution
The dissolution tests were carried out for the marketed product and indomethacin-loaded samples
prepared using VCM and HME. Prior to the test, the 20 mm VCM and HME samples were milled.
An equivalent of 50 mg of indomethacin-milled samples were used for dissolution. The 8 mm VCM
discs which were equivalent to 50 mg of indomethacin were used as an entire disc. The marketed
formulation (Indo-CT 50 mg) was used as a reference. The dissolution tests were carried out using
the Sotax AT7 smart (Sotax, Germany) dissolution tester following the USP apparatus 2 method.
The dissolution medium was 900 mL of simulated gastric fluid (SGF) at 37.5 ± 0.5 ◦C with a stirring
rate of 75 rpm. SGF was selected as a dissolution media to determine solubility of indomethacin in
stomach on oral administration. Three replicates were performed for each sample. The amount of
indomethacin dissolved was determined using the online UV–VIS method at 318 nm.
3. Results
3.1. Vacuum Compression Molding
Images of the produced VCM discs are shown in Figure 3. The VCM discs had a defined cylindrical
geometry and a yellowish appearance with all polymers. All discs were transparent, no crystals
were visible, indicating that indomethacin was dissolved in the carrier materials. The Kollidon®
VA 64 samples occasionally showed some bubbles, which might be related to residual moisture of
the material. Compared to extrusion temperature readings, VCM requires slightly higher hot plate
temperatures to compensate for non-existing shear heating. It does not mean that VCM requires
higher processing temperatures compared to the macroscopic extruder temperature readings, as the
readouts of the extruder do not capture local shear heating within the polymer melt. Temperature
increases of 20 ◦C or even more are typical values obtained by simulations conducted to evaluate shear
heating during twin-screw extrusion [41]. Table 5 shows the lossless preparation of the VCM samples
produced for a filling weight of 167 and 500 mg for 8 mm and 20 mm, respectively. The resulting
VCM samples were showing that no material was lost during VCM processing. This was statistically
analyzed by comparing before and after weights for each corresponding polymer mixtures with a
two-tailed paired t-test with a confidence interval of 95%. A p-value of more than 0.05 was obtained
for each of the comparisons indicating that the difference is non-significant. The visual inspection
indicated amorphization, and the samples were further analyzed in the subsequent analysis sections.
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The VCM samples (n = 3 for each dimension), as used to screen one formulation, required less than 2 g
of starting material, which corresponds to 1/5 of the 3-min flushing time of the small-scale extruder
chosen for this study. Further, potential downscaling using small-scale analysis tools will also allow
using smaller VCM tools, e.g., with 2 mm diameter, making screenings in the mg-scale feasible.
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Figure 3. Images of 8 mm VC disc samples loaded with 30% indomethacin (IND) (20 mm diameter
not shown, similar in appearance).
Table 5. Lossless preparation of MeltPrep® VCM samples (n = 3).
Excipients Before VCM Process Weight (mg) After VCM Process Weight (mg)
8 mm 20 mm 8 mm 20 mm
Parteck® MXP 167.51 ± 0.29 498.35 ± 0.84 166.46 ± 0.39 495.75 ± 1.77
Soluplus® 168.67 ± 1.21 502.43 ± 1.27 166.90 ± 0.56 499.20 ± 0.31
Kollidon® VA 64 167.23 ± 2.05 500.85 ± 1.57 165.47 ± 2.56 498.98 ± 1.68
Eudragit® EPO 167.24 ± 1.78 500.12 ± 0.45 165.37 ± 1.08 497.39 ± 1.32
3.2. Hot-Melt Extrusion
The extrusion was started under the parameters mentioned in Section 2.2.3. All evaluated
polymers were processed at the identified parameters. The obtained extrudates were pelletized using
a Brabender strand pelletizer (Brabender GmbH and Co. KG, Duisburg, Germany) with a pellet size of
2mm and further milled for all the evaluations (IKA tube mill 100, Staufen, Germany) to provide a
similar particle size compared to the material used for a fast disintegration tablet. All the polymers
utilized showed good extrudability under the utilized processing temperatures.
3.3. Differential Scanning Calorimetry
Thermal analytical techniques provide data about thermal stability, melting point, and
recrystallization temperatures [32]. The sharp endothermic peak at 162 ◦C corresponds to the
melting point of indomethacin (Figure 4). Parteck® MXP, Soluplus®, Kollidon® VA 64, and Eudragit®
EPO showed Tg (glass transition) temperatures of 50 ◦C, 70 ◦C, 101 ◦C, and 57 ◦C, respectively,
confirming their amorphous state (Figure 4 left). An endothermic melting peak at 180 ◦C was observed
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for the Parteck® MXP indicating its semi-crystalline nature caused by an alignment of the linear
polymer chains.
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Indomethacin was completely miscible at the concentration of 30% w/w in the polymer-carriers,
which is an important prerequisite to attain a solid dispersion. A characteristic melting endothermic
indomethacin peak was absent in the VCM and HME formulations (Figure 4 middle and right).
Thus, it confirmed that the indomethacin was present in an amorphous state in the VCM discs and
melt-extruded formulations. The semi-crystalline peak for Parteck® MXP is still observed in the VCM
formulations, proving its semi-crystalline nature which is unaffected by the VCM and HME processing.
3.4. PXRD Analysis
DSC studies indicated drug-polymer miscibility in the HME and VCM formulations. However,
DSC measurements have limited sensitivity of measuring crystalline residuals within the material.
Therefore, the solid-state of the formulations was further investigated by the PXRD analysis.
Figure 5 shows the diffractograms of the measured data of processed VCM samples as well as the
cryo-milled physical mixtures of each polymer and indomethacin. Figure 6 shows the diffractograms
of processed HME samples. The reference data of pure indomethacin show a significant crystalline
peak confirming the crystalline state of the starting material.
XRD pattern for the milled extrudate and milled VCM samples showed a complete absence of
characteristic crystalline peaks of indomethacin. Both melt processing routes (HME and VCM) deliver
comparable results. In contrast, Parteck® MXP shows a broad halo between 2θ of 19◦–25◦ confirming
the semi-crystalline nature of PVA polymer.
The solid-state of the cryo-milled mixtures, as seen in Figure 5, is already influenced via the
cryo-milling process. The effect of cryo-milling on polymorphic transformation has been reported
earlier for indomethacin [42]. The formation of an amorphous state upon cryo-milling is because of
the continuous disordering process of the indomethacin lattice [43]. This observed amorphization
in indomethacin is a cryo-milling time-dependent process, and it has been extensively studied and
reported [43,44]. In the case of Parteck® MXP and Kollidon® VA 64, this effect is seen to be more
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pronounced than in Eudragit® EPO and Soluplus®. As cryo-milling was not the objective of the study,
the observed differences in the amorphization of the physical mixtures were not further explored.
When VCM screening is applied, cryo-milling is beneficial since it provides uniform mixing
and size reduction for the physical mixture. The short cryo-milling as preconditioning decreases the
physical mixtures crystallinity by bringing the path length (particle dimensions) down to small length
scales that can make diffusion as the main mixing mechanism. The VCM process can achieve the full
amorphization of the subjected formulation without stressing the material.
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indomethacin diffractogram for reference purpose is given in the back as a single curve.
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3.5. Dissolution
Dissolution data of milled VCM samples and milled HME samples are presented in Figures 7 and 8,
respectively. Figure 9 represents the dissolution data of the entire 8 mm VCM discs. Simulated
gastric fluid (pH 1.2) was chosen to evaluate the supersaturation of indomethacin via the amorphous
matrix. The 8 mm discs were directly used for the dissolution while the 20 mm samples were milled.
The factors that played a vital role in the release behavior were the nature of the excipients and the
surface area of the samples during the dissolution study. In the case of 8 mm discs, as they were placed
intact in the dissolution medium, it had less surface area and hence very small surface was exposed to
the dissolution medium to facilitate the drug release. While the 20 mm VCM and HME samples were
milled, a large surface area was available for drug dissolution.
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The similarity between the milled VCM and HME samples is shown using the f2 similarity value.
As per the FDA guidelines, the release profiles are considered similar when the f2 value is greater
than 50. If more than 85% of the drug is released, only a single value above that is considered [45].
However, in the case of our results, the steady-state concentration for all the formulations was found to
be less than 85%. Hence, for the f2 value calculations, we considered all the timepoints from the study.
A very rapid onset can be observed for Eudragit® EPO in the milled VCM and HME samples
with a release of 45.04 ± 0.19 mg/L in 10 min and 46.00 ± 0.88 mg/L in 15 min, respectively. After an
initial supersaturation for Eudragit® EPO, precipitation occurs resulting in reduced concentrations.
After 60 min, Eudragit® EPO was able to maintain the drug concentration of at least 4.68 ± 0.20 mg/L
for milled VCM samples and 6.53 ± 0.05 mg/L for milled HME samples until the end of the study.
The observed release is due to the pH-sensitive solubility of Eudragit® EPO in gastric juices up to a
pH of 5.0 [46]. From the similarity factor (f2 value) the drug release profile for milled VCM and HME
samples is similar with the f2 value of 50.79 (Table 6).




Kollidon® VA 64 84.59
Eudragit® EPO 51.78
For the Eudragit® EPO 8 mm VCM discs, the highest concentration of 35.63 ± 2.21 mg/L was
reached in 25 min. Similar to the milled samples, after an initial supersaturation, a stable plateau
was observed at 105 min with a drug concentration of 6.88 ± 0.38 mg/L. The 8 mm VCM disc was
completely dissolved by 360 min (Figure 10) as Eudragit® EPO is highly soluble in pH 1.2, which
correlates with an initial burst release.
Parteck® MXP showed a peak drug concentration of 20.17 ± 0.70 mg/L at 120 min for milled VCM
samples and then maintained a minimum drug concentration of more than 20.10 ± 0.98 mg/L until the
end of 360 min. In the case of milled HME samples, the peak drug concentration of 23.02 ± 0.22 mg/L
was observed at 60 min, and a drug concentration of more than 17.99 ± 0.29 mg/L was maintained.
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In contrast to Eudragit® EPO, it can maintain the supersaturation for a longer timeframe. Due to its
surface-active properties, polyvinyl alcohol of Parteck®MXP can effectively stabilize the supersaturated
state for a prolonged timeframe [47].
Pharmaceutics 2020, 12, x 13 of 17 
 
 
Figure 10. VCM discs after 6 h of dissolution on weighing boats. 
For the Parteck® MXP 8 mm VCM discs, a sustained and incomplete release is observed with 
17.28 ± 0.53 mg/L in 360 min owing to the diffusion behavior from the intact matrix of the disc. In the 
case of Parteck® MXP milled HME samples and milled VCM samples had an f2 value of 70.33, 
showing that the drug release profiles are similar. 
In all the Kollidon® VA 64 formulations, a supersaturation is observed but with limited drug 
release during the entire release period. With the highest drug release of 9.29 ± 0.47 mg/L for milled 
VCM samples, 7.40 ± 1.92 mg/L for milled HME samples, and 6.58 ± 0.79 mg/L for 8 mm VCM discs 
at 360 min. The observed results can be explained as Kollidon® VA 64 at a pH of 1.2 and may 
preferentially dissolve from the matrix’s exterior by forming a drug-rich amorphous hydrophobic 
shell that inhibits the drug release [34]. As seen from Figure 10, the 8 mm VCM disc had retained its 
shape and did not show any disintegration for the drug release to occur. For the milled VCM and 
HME samples, an f2 value of 84.59 was calculated, thus proving a similar release pattern. 
Unlike the other excipients, extremely limited release from the Soluplus® was observed. In the 
milled VCM samples, a release of 12.25 ± 0.69 mg/L, and for milled HME samples, a release of 3.44 ± 
0.5 mg/L, was observed at 360 min. The f2 value of 61.19 was obtained, proving a similar release 
behavior. For the 8 mm VCM discs, the negligible release was observed with a maximum release of 
0.28 ± 0.05 mg/L. From Figure 10, we can see that Soluplus® shows water absorption and swelling 
while retaining the disc-like shape. The limited release from Soluplus® can be attributed to the 
possible formation of hydrogen bonds between the carboxylic groups on indomethacin and oxygen 
atoms in the Soluplus®. Due to the formation of hydrogen bonding at pH 1.2, there is a reduction in 
the solubility of the polymer leading to decreased release [48]. Furthermore, in the case of an 8 mm 
VCM disc, the surface area available for drug release is limited, while in the case of milled samples, 
the surface area is increased multi-folds. This increase in the surface area can explain the observed 
higher drug release from milled samples despite low solubility. 
Compared to other polymers, PVA shows at least a four times higher drug release than 
Soluplus®, Kollidon® VA 64, and the marketed formulation Indo-CT 50 mg. Furthermore, compared 
to the solubility of the pure indomethacin, Parteck® MXP enhanced the release by almost 20 times.  
The area under the curve (AUC) was calculated using the trapezoidal rule for the release profiles 
of milled HME, milled VCM, 8mm VCM disc, and the marketed product Indo-CT 50 mg (Table 7). 
Considering the obtained AUC results of milled VCM, milled HME, and 8mm discs, we can establish 
an overall ranking of the polymers for ASD. From all the polymers, Parteck® MXP showed the highest 
maintained supersaturation levels for indomethacin in the case of milled as well as 8mm disc 
samples. It was followed by Eudragit® EPO, Kollidon® VA 64, and then Soluplus®. The high 
variability of AUCs observed for Soluplus® can be attributed to the factors mentioned above like 
available surface area and hydrogen bonding. Collectively, if we compare the results obtained via the 
VCM tool to the results of the hot-melt extruded formulations in Figures 7 and 8, a remarkably similar 
pattern can be observed. This highlights the high predictability of the MeltPrep® VCM technology. 
The performance of different polymers can be assessed at a low sample size and provide high 
reliability of prediction. 
  
Figure 10. VCM discs after 6 h of dissolution on weighing boats.
For the Parteck® MXP 8 mm VCM discs, a sustained and incomplete release is observed with
17.28 ± 0.53 mg/L in 360 min owing to the diffusion behavior from the intact matrix of the disc. In the
case of Parteck® MXP milled HME samples and milled VCM samples had an f2 value of 70.33, showing
that the drug release profiles are similar.
In all the Kollidon® VA 64 formulations, a supersaturation is observed but with limited drug
release during the entire release period. With the highest drug release of 9.29 ± 0.47 mg/L for milled
VCM samples, 7.40 ± 1.92 mg/L for milled HME samples, and 6.58 ± 0.79 mg/L for 8 mm VCM
discs at 360 min. The observed results can be explained as Kollidon® VA 64 at a pH of 1.2 and may
preferentially dissolve from the matrix’s exterior by forming a drug-rich amorphous hydrophobic shell
that inhibits the drug release [34]. As seen from Figure 10, the 8 mm VCM disc had retained its shape
and did not show any disintegration for the drug release to occur. For the milled VCM and HME
samples, an f2 value of 84.59 was calculated, thus proving a si ilar release pattern.
Unlike the other excipients, extremely limited release from the Soluplus® was observed. In the
milled VCM sampl s, a release of 12.25 ± 0.69 mg/L, and for milled HME samples, a release of
3.44 ± 0.5 mg/L, was observed at 360 min. The f2 value of 61.19 wa obtained, proving a similar release
behavior. For the 8 mm VCM discs, the negligible release was observed with a maximum release of
0.28 ± 0.05 mg/L. From Figur 10, we can see that Soluplus® shows water bsorption and swelling
while retaining the disc-like shape. The limited release f om Soluplus® ca be attributed to the possible
formation of hydrogen bonds betw en the carboxylic groups indomethacin and oxygen atoms in the
Soluplus®. Due to the for ation of hydrogen bonding at pH 1.2, there is a reduction in the solubility
of the polymer leading to decreased release [48]. Furthermore, in the case of an 8 mm VCM disc,
the surface area available for drug release is limited, while in the case of milled samples, the surface
area is increased multi-folds. This increase in the surface area can explain the observed higher drug
release from milled samples despite low solubility.
Compared to other polymers, PVA shows at least a four times higher drug release than Soluplus®,
Kollidon® VA 64, and the marketed formulation Indo-CT 50 mg. Furthermore, compared to the
solubility of the pure indomethacin, Parteck® MXP enhanced the release by almost 20 times.
The area under the curve (AUC) was calculated using the trapezoidal rule for the release profiles
of milled HME, milled VCM, 8mm VCM disc, and the marketed product Indo-CT 50 mg (Table 7).
Considering the obtained AUC results of milled VCM, milled HME, and 8mm discs, we can establish
an overall ranking of the polymers for ASD. From all the polymers, Parteck® MXP showed the highest
maintained supersaturation levels for indomethacin in the case of milled as well as 8mm disc samples.
It was followed by Eudragit® EPO, Kollidon® VA 64, and then Soluplus®. The high variability of
AUCs observed for Soluplus® can be attributed to the factors mentioned above like available surface
area and hydrogen bonding. Collectively, if we compare the results obtained via the VCM tool to the
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results of the hot-melt extruded formulations in Figures 7 and 8, a remarkably similar pattern can be
observed. This highlights the high predictability of the MeltPrep® VCM technology. The performance
of different polymers can be assessed at a low sample size and provide high reliability of prediction.






Parteck® MXP 7196.02 ± 1.09 6940.29 ± 3.96 3778.45 ± 1.25
Soluplus® 1053.25 ± 14.22 3421.46 ± 7.52 57.31 ± 22.96
Kollidon® VA 64 1752.93 ± 25.91 2459.68 ± 6.43 1725.85 ± 14.17
Eudragit® EPO 3855.90 ± 5.74 2557.37 ± 2.38 3140.94 ± 7.94
Marketed Product—Indo-CT 50 mg—933.33 ± 20.86 mg·L−1·min.
4. Conclusions
In this study, the MeltPrep® VCM technology was assessed as a potential screening tool for
melt-based formulations at a small scale, where we also demonstrated the loss-less processing.
Indomethacin as a model drug was utilized for the preparation of solid dispersions using HME
and VCM technology. The primary objective of the study was to compare the formation of ASDs to
enhance the solubility of indomethacin and to assess the similarity between the two technologies.
It was determined through the comparison of thermal analysis, PXRD, and dissolution profiles. From
the DSC thermograms and PXRD diffractograms, we confirmed that an amorphous solid dispersion
was formed using both the technologies. This was further proved by similar dissolution profiles
indicating the comparability of the VCM samples to that of the HME. Hence, proving our objective of
utilizing VCM as an explorative tool for HME-based formulations. With a fast preparation time, small
sample amount requirements, and with choice of different sample sizes and shapes, VCM will be a
feasible predictive tool for extruded formulations, especially on a small scale.
We could demonstrate the application of VCM technology for a set of widely used polymers
in HME, especially showing a clear advantage for hydrophilic polymers, which would be potentially
excluded by a standard film casting screening. Further processing of VCM samples such as milling can
mimic particle properties as they would be obtained from milled extrudates enabling down-streaming
to a conventional tablet design.
When comparing the efficiency, Parteck® MXP showed better results among all selected polymers.
It was able to show a sustained drug release as well as maintained a steady-state concentration at
a much higher level compared to other polymers. Even though Eudragit® EPO showed an initial
burst release, the drug concentration quickly dropped down and was sustained at a very low value
compared to initial supersaturation concentration. While Soluplus® and Kollidon® VA 64 showed a
drug release of less than 20% in 360 min.
One advantage of the early screening technology is to identify potential interactions between
drug substances and test polymers at early development stages like the observed low drug release in
the case of Soluplus®. VCM utilizes small quantities of material compared to HME, thus preventing
the wastage of material in early development screening.
A visual analysis of the samples during the dissolution process can provide important insight
into the release mechanism. Understanding molecular interactions within the matrix can support the
identification of the best possible carrier at the early stages.
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